Areterna and Biomay announce strategic partnership for mRNA manufacturing
Collaboration expands Areterna’s reach in Europe and strengthens Biomay’s mRNA CDMO offerings.
Collaboration expands Areterna’s reach in Europe and strengthens Biomay’s mRNA CDMO offerings. Areterna LLC, a company with a mission to democratize mRNA products by supplying low-cost GMP raw materials, today announced it has entered a strategic partnership with Biomay, a seasoned CDMO that offers GMP manufacturing of mRNA, plasmid DNA and recombinant proteins.
This partnership will allow European and American customers access to Areterna’s low-cost and royalty-free cap analogs as well as animal-origin-free nucleoside triphosphates (NTPs) and modified NTPs. “Biomay is a CDMO we admire. Established for 40 years, it has more than 15 years of GMP manufacturing experience. Biomay has manufactured hundreds of GMP batches including not only clinical but also commercial products,” said May Guo, Chief Commercial Officer of Areterna. “It’s a pleasure to work with a high-caliber CDMO like Biomay. Customers will have peace of mind by working with a site that recently has passed FDA inspection. With the help of Areterna´s raw materials, Biomay can bring more value to its customers.”
Through the partnership, Biomay will profit from Areterna’s expertise in mRNA design, LNP formulation, process development and analytical development. “Areterna is more than a raw material supplier. The company has its own veterinary mRNA vaccine pipeline. By developing its own mRNA vaccines, Areterna has built its expertise in mRNA and LNP manufacturing, QC analysis and functional testing,” said Hans Huber, Chief Executive Officer of Biomay, “We can leverage Areterna’s expertise in helping our mRNA customers such as trouble shooting the upstream process or developing construct specific analytical methods. Biomay has recently finalized a number of cGMP mRNA batches by utilizing various cap analogs from Areterna. We are highly satisfied in terms of performance, yield and quality.”